CD274 and non-small cell lung carcinoma: Furthermore, a phase III trial showed that definitive chemoradiotherapy (CRT) followed by administration of durvalumab, a PD-L1 antibody, prolonged overall survival in patients with locally advanced non-small-cell lung cancer (NSCLC) [3, 4].